A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
A phase 1/2 trial of Enzalutamide in diffuse large b-cell lymphoma and mesothelioma, run by Novartis Pharmaceuticals, now recruiting.
Overview
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas is a phase 1/2 interventional study registered as NCT04104776 by Novartis Pharmaceuticals, with 300 participants planned, started 2019-09-18 and due to reach its primary completion in 2030-02-27. Interventions recorded: Tulmimetostat, Enzalutamide. Conditions listed: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Enzalutamide, Novartis, Prostate cancer.
- TrialStudy of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
Shares Enzalutamide, Prostate cancer.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Enzalutamide, Novartis, Prostate cancer.
- TrialAn Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo
Shares Enzalutamide, Prostate cancer.
- TrialPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Shares Novartis, Diffuse large B-cell lymphoma.
- TrialStudy of Out of Specification for Tisagenlecleucel
Shares Novartis, Diffuse large B-cell lymphoma.
- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Shares Novartis, Prostate cancer.
- TrialZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Shares Enzalutamide, Prostate cancer.